Abstract:Angiotensin-converting enzyme (ACE) inhibitors are used primarily in the treatment of hypertension, heart failure, and in the acute phase of myocardial infarction. Lisinopril [N2-[(1S)-1-car-boxy-3-phenylpropyl]-L-lysyl-L-proline], enalapril [(S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline] and ramipril [2-aza-bicyclo-[3.3.0]-octane-3-carboxylic acid] are all five-membered heterocycles and three of the most prevalent ACE inhibitors in clinical use worldwide. ACE inhibitor-induced angioedema (AE) is clinically characterized by self-limited edema of the dermis and subcutaneous lipid tissue, localized on face skin, oral mucosa and tongue in most cases. However, severe episodes of intestinal AE misdiagnosed as acute appendicitis and laryngeal AE requiring incubation have been reported. The pathophysiology of ACE inhibitor-induced angioedema is attributed to the accumulation of bradykinin, which is a potent vasodilator with proinflammatory activity that is normally degraded by angiotensin-converting enzyme (ACE) and aminopeptidase P; however, a small proportion of treated patients is affected. Given that patients do not respond to anti-H1 antihistamines and steroids, early clinical recognition and discontinuation of the ACE inhibitors are the treatments of choice for the long-term management of ACE inhibitor- induced angioedema. The search period of the present review was set up until November 2023, and its aim is to shed light on the broader context of ACE inhibitor-induced angioedema, exploring aspects such as clinical presentation, pathophysiology, and therapeutic considerations in this potentially life-threatening condition. The exploration of alternative drug options such as angiotensin II receptor blockers, the potential association of coadministration of DPP-4 inhibitors with ACE inhibitors, the presentation of angioedema and the significant clinical importance of this condition are also discussed. By focusing on the chemical structure of ACE inhibitors, specifically their nitrogen-based heterocycles—an attribute shared by over 880 drugs approved by the FDA within the pharmaceutical industry—this review emphasizes the pivotal role of nitrogen scaffolds in drug design and underscores their relevance in ACE inhibitor pharmacology.

S4714 Small Bowel Angioedema Secondary to ACE Inhibitor

S4910 Gastroenterologist's Recognition of Rare Adverse Drug Effect Prevents Further Harm in a Patient with Small Bowel Obstruction Due to Lisinopril: A Case Report and Literature Review

Angiotensin-converting Enzyme Inhibitor Reduces Scar Formation by Inhibiting Both Canonical and Noncanonical TGF-β1 Pathways

Assessment of the Effect of Angiotensin Converting Enzyme Inhibitor on the Flexibility of Abdominal Aortic Wall in Patients with Hypertensive Disease Using Doppler Tissue Imaging

Five-Membered Nitrogen Heterocycles Angiotensin-Converting Enzyme (ACE) Inhibitors Induced Angioedema: An Underdiagnosed Condition

Angiotensin‐converting Enzyme Inhibitor Works As a Scar Formation Inhibitor by Down‐regulating Smad and TGF‐β‐activated Kinase 1 (TAK1) Pathways in Mice

Imaging Review of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema of the Head and Neck

S4820 Splenic Marginal Zone Lymphoma Manifesting as Acquired Angioedema of the Small Intestine

Exemestane-Everolimus-Induced Angioedema in a Woman With Metastatic Breast Cancer: A Case Report and Review

S4934 Recurrent Bowel Angioedema in a Patient With Normal C1 Esterase: A Diagnostic Conundrum

Intestinal angioedema caused by an acquired C1 esterase inhibitor deficiency associated with underlying splenic marginal zone lymphoma

Tranexamic acid for angiotensin converting enzyme inhibitor induced angioedema: A retrospective multicenter study

ADRs and Clinical Rational Use of Angiotensin Converting Enzyme Inhibitor

Inhibition of ACE Activity Contributes to the Intestinal Structural Compensation in a Massive Intestinal Resection Rat Model

Unilateral tongue swelling: an unusual presentation of angiotensin-converting enzyme inhibitor-related angioedema

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Acute Abdominal Pain as the Initial Presentation of an Acquired C1 Inhibitor Deficiency

S4779 Olmesartan's Hidden Side: Unveiling an Uncommon Cause of Chronic Diarrhea

Antihypertensive medication and the risk of acute pancreatitis: The European case-control study on drug-induced acute pancreatitis (EDIP)

Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug